The aims of the first proficiency evaluation of the Diabetes Antibody Standardization Program (DASP) were to assess general implementation of assay methods and to evaluate the new World Health Organization (WHO) reference reagent for autoantibodies to GAD and IA-2. Forty-six laboratories in 13 countries received coded sera from 50 patients with newly diagnosed type 1 diabetes and 50 blood donor control subjects, together with the WHO reference reagent and diluent serum. Results were analyzed using receiver operator characteristic (ROC) curves. Sensitivity was adjusted to 90% specificity in workshop controls. The median adjusted sensitivity for GADA (45 laboratories) was 84% (range 62–96%), for IA-2A (43 laboratories) was 58% (50–74%), and for insulin autoantibody (IAA; 23 laboratories) was 36% (13–66%). ROC curve analysis showed all GADA and IA-2A assays, and 18/23 IAA assays found significant differences between patients and control subjects. There was good concordance between laboratories in ranking of samples by GADA and IA-2A levels or if results were expressed in relation to the WHO reference reagent. Assays that achieved the highest sensitivity for IAA were also concordant in ranking samples, but overall concordance for IAA was poor. Differences in assay protocols between laboratories must be addressed so that all centers and kit manufacturers can perform to the same high standard.

Autoantibodies against islet cell antigens are important markers of diabetes-associated autoimmunity. Their measurement is widespread and used to identify people at increased risk for developing type 1 diabetes (1) or requiring insulin treatment (2), to aid in the classification of diabetes (3), to study the natural history of diabetes (4,5), and to measure efficacy in intervention trials.

Concordance of the results obtained from different laboratories is essential for comparison of studies from different centers and is increasingly important in recruitment into multicenter studies. This issue has been addressed in a series of international workshops and antibody standardization and proficiency programs since the first islet cell antibody (ICA) standardization workshop in 1985 (6,7). Subsequent workshops examined other islet autoantibodies as they were described, and the combined islet autoantibody workshop in 1995 included antibodies to GAD, protein tyrosine phosphatase IA-2, and insulin, as well as ICA. (8). The major achievements of these activities have been the introduction of a reference standard preparation and units for ICA measurement, validation of diabetes-associated antibody markers and methods for their measurement, and an improved concordance between laboratory measurements (6,8). The ICA reference standard has recently been given World Health Organization (WHO) status and undergone preliminary evaluation in a small number of laboratories as a reference reagent for autoantibodies to GAD and IA-2 (9).

The Diabetes Antibody Standardization Program (DASP), an extension of Immunology of Diabetes Society autoantibody workshop activities, was established in collaboration with the U.S. Centers for Disease Control and Prevention to evaluate and improve general implementation of assay methods and to undertake extended evaluation of the new WHO international reference reagent for antibodies to GAD and IA-2. The aim of the first proficiency evaluation was to assess and improve comparability of islet autoantibody measurements between laboratories in preparation for multicenter studies. To achieve this, coded sera were used to evaluate individual laboratory performances for measurement of autoantibodies to GAD, IA-2, and insulin (IAA) and to determine how the GAD and IA-2 antibody reference standard preparation should be used to enable reporting of common international units.

### Sera.

Sera were obtained from 50 patients with newly diagnosed type 1 diabetes (median age, 17 years; range, 9–31). Of these, 19 were female and 31 were male, 49 were white and 1 was Hispanic. All samples were collected within 14 days of starting insulin treatment (median, 4.5 days). Control sera were obtained from 50 U.S. blood donors (median age 20 years; range 18–28). Sera were prepared in 100-μl aliquots and frozen. Coded sera were distributed to 46 laboratories in 13 countries (see appendix for listing of participating laboratories). Each participating laboratory received 1–3 uniquely coded sets of sera depending on the volume requirements of their assays. Sera from different sets could not be combined, so only those assays that used <100 μl could be included in the evaluation.

Laboratories were asked to test the sera with whatever relevant assays were currently in use for detection of prediabetes. Of the participating laboratories, 45 reported results for GAD antibodies, 43 for IA-2/ICA512 antibodies, and 23 for IAA. One laboratory reported results for antibodies to a GAD65/IA-2ic fusion protein and two for ICA testing by indirect immunofluorescence.

In addition, each laboratory received a lyophilized aliquot of the new WHO international reference reagent for GAD and IA-2 antibodies (97/500) (9) together with negative diluent serum. Laboratories were asked to test the standard (250 units/ml) undiluted and 1:2, 1:4, 1:8, 1:16, and 1:64 dilutions as well as the negative diluent in every GAD and IA-2 antibody assay run.

### Data analysis

#### Sensitivity and specificity.

Laboratory-defined sensitivity for each assay was calculated as the percentage of sera from patients with newly diagnosed diabetes reported as positive using the laboratory’s own cutoff. Laboratory-defined specificity was calculated as the percentage of healthy control sera reported as negative using the same threshold.

Receiver operator characteristic (ROC) curve analysis was used to evaluate the performance of each assay in discriminating disease from nondisease. The area under the curve (AUC) with 95% CI was calculated assuming a nonparametric distribution. An AUC of 1.00 would indicate that the test achieved 100% accuracy in identifying disease, and an AUC of 0.00 would indicate that all disease and nondisease sera were misclassified on the basis of the test result. Each ROC curve was tested against a null hypothesis that the AUC was 0.5, which would indicate that the test achieved random assignment of disease/nondisease status.

To facilitate additional comparison between laboratories using very different thresholds for positivity, the coordinates of the ROC curve were used to identify the level of sensitivity achieved with 1-specificity of 0.1, which was defined as the adjusted sensitivity90 (AS90). This threshold was selected to minimize the effect of outlier antibody levels in the limited number of control sera tested. It is not suggested that this is a clinically appropriate threshold. The validity of these measures was assessed by relating them to other parameters, including laboratory-defined sensitivity and specificity and concordance of antibody levels.

#### Concordance of autoantibody levels in different assays.

For comparing relative levels of autoantibody in different assays, the diabetic sera were ranked from highest to lowest for each assay. For each serum, the rank in each assay was then plotted on the y-axis, with the sera arranged in order of ascending median rank along the x-axis. Concordance was assessed by linear regression of individual assay rank versus the median rank for all sera from patients with type 1 diabetes. Differences in the concordance of ranking in subgroups of laboratories were analyzed by comparing the variance of the regression in an F test.

#### Signal:noise ratio.

The signal:noise ratio for each GAD and IA-2 antibody assay was calculated as the median cpm in patient samples reported positive in >50% of laboratories divided by the median cpm in control samples reported negative in >75% of laboratories. This parameter could not be calculated for IAA assays, as many laboratories had reported only Δ cpm with and without cold insulin.

#### Estimation of limit of detection.

The lower limit of detection in relation to the WHO standard was determined for each GAD and IA-2 antibody assay. The threshold was defined from the variability of measurement in control sera and calculated as (median cpm or OD) + 2 * (SD of the difference between duplicates). The limit of detection was defined as the dilution of the WHO standard with median cpm or OD immediately above the threshold. Three control sera that were reported as GAD antibody positive in >25% of laboratories were excluded from the calculation of limit of detection for these markers.

#### Evaluation of the use of the WHO standard in antibody quantification.

The WHO international reference reagent for GAD and IA-2 antibodies (97/500) has been defined as containing 100 units per vial (250 units/ml) (9). WHO units for GAD and IA-2 antibodies were calculated as: 1) an index related to the reference material using the formula

$Units;{=}250{\ast}\ \frac{{[}cpm\ or\ OD\ (unknown)\ {-}\ cpm\ or\ OD\ (negative\ diluent\ serum){]}}{{[}cpm\ or\ OD\ (WHO\ standard)\ {-}\ cpm\ or\ OD\ (negative\ diluent\ serum){]}}$

2) units derived from a logarithmic standard curve constructed from dilutions of the WHO reference reagent. Units assigned to individual dilutions were 125 units/ml for 1:2, 62 units/ml for 1:4, 31 units/ml for 1:8, 16 units/ml for 1:16, and 4 units/ml for 1:64. For comparing the two methods of unit derivation, the median and interquartile range of reported units for each of the 50 patient sera were compared using the Wilcoxon matched pairs test.

Results were reported from 46 assays (Table 1). Laboratory-defined sensitivity using each laboratory’s own cutoff ranged from 58 to 88%, the majority of assays reporting very similar sensitivity (median, 77%; interquartile range, 74–80%). Laboratory-defined specificity ranged from 80 to 100% and again was similar in the majority of assays (median, 94%; interquartile range, 92–98%). Samples from 30 patients and no control subjects were reported positive in ≥95% of assays; an additional 8 patients and 2 control subjects were reported positive in >50% of assays, and another 2 patients and 1 control subject were positive in >25% of assays (Fig. 1A). Agreement in >95% of assays was observed for 77 samples (34 patient samples and 43 control samples). The ranking of the GAD antibody titer in the patient samples was highly concordant between laboratories (r = 0.96, P < 0.0001; Fig. 1B).

### IA-2 antibodies.

Results were reported from 44 assays (Table 2). Laboratory-defined sensitivity ranged from 40 to 88%, the majority of assays reporting very similar sensitivity (median, 57%; interquartile range, 54–58%). Laboratory-defined specificity ranged from 28 to 100% and again was similar in the majority of assays (median, 99%; interquartile range, 96–100%). Samples from 23 patients and no control subjects were reported positive in ≥95% of assays; an additional 5 patients were reported positive in >50% of assays, and another 1 patient was positive in >25% of assays (Fig. 2A). Agreement in >95% of assays was observed for 81 samples (41 patient samples and 40 control samples). The ranking of the IA-2 antibody titer in the patient samples was highly concordant between laboratories (r = 0.89; P < 0.0001; Fig. 2B). Samples with median rank <22 were those reported negative in the majority of assays, and the expected large scatter was observed. Two patient samples (median ranks 26 and 29) had clearly dichotomous results. These were reported as negative with ranks of 3–19 and 6–15 in all assays using the human IA-2256–556/630–979 antigen and positive with ranks of 22–33 and 25–43 in assays using IA-2ic or full-length IA-2 antigen.

### IAA.

Results were reported from 23 assays (Table 3). Laboratory-defined sensitivity ranged from 4 to 42% (median, 14%; interquartile range, 7–25%). Laboratory-defined specificity ranged from 89 to 100% (median, 100%; interquartile range, 98–100%). Only four assays reported IAA in >30% of patient samples (all four had laboratory-defined specificity of 98 or 100%). Samples from two patients and no control subjects were reported positive in >95% of assays (Fig. 3A). An additional four patients and no control subjects were reported positive in >50% of assays, and a further three patients were reported positive in >25% of assays. For 74 samples (26 patient samples and 48 control samples), >95% of assays were in agreement. Although the concordance of ranking of the IAA titer in the patient samples between laboratories was significant (r = 0.56; P < 0.0001), it was clearly inferior to that observed for GAD and IA-2 antibodies (P < 0.0001; Fig. 3B).

Using ROC curves, 5 of 23 laboratories did not find significant differences between patients and control subjects (P > 0.05). Performance characteristics varied substantially (median AUC, 0.67; interquartile range, 0.60–0.74; median AS90, 36%; interquartile range, 26–47). AUC and AS90 were positively correlated with the assay-reported sensitivity (r = 0.5, P < 0.02; r = 0.6; P < 0.005). Six assays (laboratories 116, 120, 121, 126, 133, and 153) had both AUC and AS90 values in the upper 25th centile. All six assays used in-house microradiobinding assays with 125I-labeled insulin as previously described (10,11,12). Laboratory-defined sensitivity in these six assays ranged from 14 to 36% (median, 31%). Five laboratories (laboratories 105, 117, 132, 135, and 136) had both AUC and AS90 in the lower 25th centile. These included two of the three participating laboratories using a commercially available radiobinding assay with 125I insulin. Concordance in ranking of patient samples was markedly higher between the assays with AUC and AS90 in the upper 25th centile (r = 0.8, variance = 70.3) than between the remaining assays (r = 0.56, variance = 130; P < 0.0001; Fig. 3B and C).

### Other assays.

The radioimmunoassay for antibodies to GAD65/IA-2ic fusion protein achieved 88% sensitivity with 100% specificity. The AUC was 0.960 (95% CI, 0.92–1.00) and AS90 0.90. Of the two ICA assays participating in the workshop, one (laboratory 137) achieved 90% sensitivity with 98% specificity, and the other (laboratory 120) achieved 68% sensitivity with 100% specificity.

### WHO reference reagent.

The limits of detection of GAD and IA-2 antibodies, expressed as dilutions of the WHO standard, are shown in Tables 1 and 2. The undiluted WHO standard (250 units/ml) was above the limit of detection of all GAD and IA-2 antibody assays. The median limit of detection of the participating GAD antibody assays was the 1:16 dilution (16 units/ml). In seven assays, the limit of detection was below the 1:64 dilution (4 units/ml). The median limit of detection of IA-2 antibody assays was below the 1:64 dilution (4 units).

### Use of common units derived from the WHO standard.

The range of GAD and IA-2 antibody levels expressed as WHO units/ml for the 50 patient samples is shown in Fig. 4. Units were slightly but significantly higher when calculated as an index than when derived from a standard curve for GAD antibodies (median 181 vs. 179 units/ml; P = 0.0004, Wilcoxon paired test) and IA-2 antibodies (median 78 vs. 67 units/ml; P = 0.0002, Wilcoxon paired test). For GAD antibodies, the interquartile ranges of reported units did not differ significantly between index- and standard curve-derived units (P = 0.065, Wilcoxon paired test). For IA-2 antibodies, the interquartile ranges of index-derived units were significantly lower than those of standard curve-derived units (P = 0.005, Wilcoxon paired test). Antibody levels measured in assays using IA-2256–556/630–979 antigen were lower than those from assays using IA-2ic or full-length IA-2 antigens, whether units were derived from an index or a standard curve (P < 0.002, Mann-Whitney U test).

The first DASP proficiency evaluation has demonstrated a remarkable degree of concordance between laboratories in GAD and IA-2 antibody measurement using radiobinding assays. This has been achieved much more quickly than by previous efforts to standardize ICA assays. The format and size of the workshop, together with the methods of analysis used, allowed fuller evaluation of assay performance than has been possible in small-scale proficiency schemes. Concordance between laboratories was directly related to their capacity to distinguish patient and control samples as defined in the ROC analysis. This was in turn related to assay type, antigen, and signal:noise ratio. For both GAD and IA-2 antibodies, only radiobinding assays achieved high sensitivity and specificity. For IA-2 antibodies, radiobinding assays that used the IA-2256–556/630–979 antigen had lower sensitivity than assays that used intact intracellular IA-2. Samples from two patients had antibodies against the intracellular IA-2 but not against the IA-2256–556/630–979 spliced form. For GAD antibodies but not for IA-2 antibodies, high sensitivity was also associated with higher assay signal:noise ratio. This difference may be attributable to higher signal:noise ratios in IA-2 antibody assays, which makes this variable less likely to be the limiting factor in determining sensitivity. Finally, the laboratories that were least able to distinguish patient and control samples were often the same for both GAD and IA-2 antibody assays.

An important aspect of this study was the evaluation of general introduction of common units for measurement of GAD and IA-2 antibodies, based on the WHO reference preparation. The value of introducing a common standard to allow laboratories to express GAD and IA-2 antibody results in common units was confirmed, and the Immunology of Diabetes Society now recommends that results be expressed as WHO units/ml. Two methods for deriving units were compared: an index calculated from the ratio of test sample to a single standard and units derived from a standard curve of multiple dilutions over high and low antibody levels. Small but statistically significant differences were observed using these two methods. Index-based units were consistently marginally higher than those derived using a standard curve. For GAD antibodies, between laboratory variation, measured as the interquartile range, was not significantly different between units derived from an index or from a standard curve. For IA-2 antibodies, however, the interlaboratory variation in units derived from an index was significantly less than in units derived from a standard curve. Supplies of the WHO reference reagent are limited, and laboratories will not be able to include this as a standard in all assays but will need to calibrate their own laboratory standards to the reference reagent. As comparability between laboratories was not improved by use of a standard curve, except perhaps at very low antibody levels (data not shown), it is concluded that laboratory standards should be calibrated to the undiluted WHO reference reagent using the more simple index method. It should be noted, however, that the use of multiple-point standard curves would be expected to be of greatest benefit in reducing variation within a laboratory over time and is likely to be useful in this context, although it has not been possible to address this issue in this workshop.

In contrast, there was wide variation between IAA assays in this workshop, and although a number of sensitive assays were identified, the overall performance of IAA assays was poor. In previous workshops, the majority of IAA assays were based on polyethylene glycol precipitation of immune complexes and used serum volumes of up to 600 μl (13), whereas this workshop was limited to assays that used a maximum of 100 μl per test sample. As a consequence, the majority of laboratories used a version of the recently introduced IAA microassays using protein A precipitation (10). Of the IAA microassays in the workshop, six had sensitivity >30% and these assays were highly concordant in their ranking of samples. The workshop demonstrated, however, that most laboratories have yet to optimize the IAA assay performance and that significant effort is needed to transfer the IAA microassays successfully to a larger number of laboratories. The introduction of a reference standard preparation, as has been done for ICA, GAD, and IA-2 antibodies, will be important.

In this set of samples, GAD antibody determination by radiobinding assays achieved higher sensitivity than testing for IA-2 antibodies or, as expected in patients of this age, IAA (Fig. 5). Sensitivity could be maximized by testing for both GAD and IA-2 antibodies. Of the patient samples, 88% were defined as GAD and/or IA-2 antibody positive in at least 80% of assays. One laboratory, using a radiobinding assay for antibodies to a GAD65/IA-2ic fusion protein, achieved 88% sensitivity with 100% specificity and the highest area under the ROC curve overall. The potential of ICA determination by indirect immunofluorescence to be the most sensitive single test was confirmed in this workshop, although this was achieved by only one laboratory. Previous workshops, however, have demonstrated the great problems of standardizing this assay.

Most of the laboratories that participated in this evaluation are primarily involved in research. Islet antibody testing, however, is likely to be increasingly used in clinical practice and may need to be performed in nonspecialist laboratories. It is therefore of interest that, particularly for IA-2 antibodies, some assay kits achieved good discrimination between cases and controls with AUC and AS90 above the 75th centile. The format of this proficiency evaluation allows much fuller blinded evaluation of the performance of a kit than is generally possible. It is therefore hoped that more kit manufacturers will participate in DASP activities in the future.

In summary, the first DASP proficiency evaluation and the format of analysis have shown that, in the majority of participating laboratories, GAD and IA-2 antibody assays perform well. It has been possible to identify GAD antibody, IA-2 antibody, and IAA assays that achieve high sensitivity and specificity so that the characteristics associated with good levels of discrimination between disease and nondisease can be defined. This should allow laboratories that are not yet performing to the highest standards to identify areas for improvement. The validity of using both the index and multiple-point methods for deriving common units from the WHO standard preparation has been demonstrated, and it has been shown that good interlaboratory concordance is achieved when antibody levels are expressed in terms of WHO units. On the basis of these results, the Immunology of Diabetes Society now recommends that all GAD and IA-2 antibody results be expressed in WHO units/ml. The evaluation has also demonstrated that although the recently introduced IAA microassays can achieve high levels of sensitivity and good interlaboratory concordance; the sensitivity of these assays as implemented in most laboratories is low and must be improved. These results will be invaluable in the design, implementation, and interpretation of multicenter trials and studies in type 1 diabetes.

Manou Batstra, Department of Immunology, Diagnostic Center SSDZ, Delft, The Netherlands; Robyn Baume and Charles Verge, South Eastern Sydney Lab Services, Prince of Wales Hospital, Randwick, New South Wales, Australia; Margaret T. Behme, Diabetes Autoimmunity Laboratory, Siebens-Drake Research Institute, London, ON, Canada; Corado Betterle and Renato Zancetto, Autoimmune Endocrine Laboratory, Department of Medical and Surgical Sciences, University of Padova, Italy; Bernd Bierwolf, Medipan Diagnostica, Selchow, Germany; Emanuele Bosi and Ezio Bonifacio, San Raffaele Institute, Milan, Italy; Luis Castano and Ramon Bilbao, Endocrinology and Diabetes Research Group, Hospital de Cruces, Baracaldo, Bizkaia, Spain; Michael Christie, GKT School of Medicine, University of London, United Kingdom; Corrado Cilio and Anita Nilsson, Wallenburg Laboratory, Department of Endocrinology, University of Lund, Sweden; Peter Colman and Shane Gellert, Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Victoria, Australia; Andrew Cotterill and David Cowley, Departments of Biochemistry and Pediatric Endocrinology, Mater Health Services, Brisbane, Queensland, Australia; Terri Daniels and Ake Lernmark, R H Williams Laboratory, University of Washington, Seattle, Washington; Massimo Pietropaolo and Dorothy Becker, Rangos Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania; Francesco Dotta and Claudio Tiberti, Department of Clinical Sciences-Endocrinology, University of Rome “La Sapienza,” Rome, Italy; Toru Egashira, BML Inc. (Biomedical Lab), Saitama, Japan; Tamir Ellis and Clive Wasserfall, Center for Immunology and Transplantation, University of Florida, Gainesville, Florida; Jadwiga Furmaniak, FIRS Labs, RSR Ltd, Llanishen, Cardiff, United Kingdom; Vinod Gaur and Santica Marcovina, Diabetes Endocrinology Research Center Immunoassay Laboratory, University of Washington, Seattle, Washington; Pat Goubert and Frans Gorus, Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium; Mohammed Hawa and David Leslie, Department of Diabetes and Metabolism, St. Bartholomew’s Hospital, London, United Kingdom; Ari Hinkkanen, Department of Biochemistry, Abo Akademi University, Turku, Finland; Akira Kasuga, Department of Internal Medicine, Keio University School of Medicine, Tokyo Denroyoku Hospital, Tokyo, Japan; Eiji Kawasaki, The First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan; Rose Kientsch-Engel, Roche Diagnostics, Penzberg, Germany; Clemens Jaeger, Immunology Laboratory, Med Klinik 3, Giessen, Germany; James La Gasse and William Hagopian, Pacific Northwest Research Institute, Seattle, Washington; Claire Levy-Marchal, Inserm Unit 457, Hôpital Robert Debré, Paris, France; Tihamer Orban, Joslin Diabetes Center, Boston, Massachusetts; Angie Pollard, Endocrine and Diabetes Unit, University Department of Paediatrics, Women’s and Children’s Hospital, North Adelaide, Australia; Santica M. Marcovina, Dyamid Diagnostics, c/o Diabetes Endocrinology Research Center, Immunoassay Laboratory, University of Washington, Seattle, Washington; Didac Mauricio, Endocrine Research Laboratory, Hospital de Sant Pau, Barcelona, Spain; Patricia Mueller, Centers for Disease Control and Prevention, Atlanta, Georgia; Silvia Pinach and Gianfranco Pagano, Laboratorio di Diabetologia e Malattie del Ricambio, Department of Internal Medicine, Molinette Hospital, Turin, Italy; Alberto Pugliese and Markus Zeller, Diabetes Research Institute, University of Miami, Miami, Florida; Wiltrud Richter, Department of Orthopedic Surgery, University of Heidelberg, Heidelberg, Germany; Matti Ronkainen, Petri Kulmala, and Mikael Knip, Department of Paediatrics, Oulu University, Oulu, Finland; Merrill Rowley and Shahnaz Fida, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia; Carani Sanjeevi, Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden; Michael Schlosser and Manfred Ziegler, Institute of Pathophysiology, University of Greifswald, Karlsburg, Germany; Joachim Seissler, Diabetes Research Institute, University of Duesseldorf, Duesseldorf, Germany; Goran Sundkvist and Henrik Borg, Islet Antibody Laboratory, Wallenberg Laboratory, University of Lund, Lund, Sweden; Carina Torn and Mona Landin-Olsson, Diabetes Laboratory, University Hospital, Lund, Sweden; Alistair Williams and Polly Bingley, Division of Medicine, University of Bristol, Bristol, United Kingdom; Ana Maria Yamamoto, Immunology, Necker Hospital, Paris, France; Liping Yu and George Eisenbarth, Barbara Davis Center, University of Colorado, Denver, Colorado; and Anette Ziegler, Diabetes Research Institute of the Academic Hospital Munchen-Schwabing, Munich, Germany.

FIG. 1.

GAD autoantibodies in samples from 50 patients with newly diagnosed type 1 diabetes in the DASP-1 proficiency evaluation. A: The proportion of assays reporting each sample as GAD autoantibody positive on the basis of the laboratory-defined cutoff. B: The rank of individual samples in each assay versus the median rank obtained for all 46 participating assays. Samples are arranged in the order of their median rank in all assays.

FIG. 1.

GAD autoantibodies in samples from 50 patients with newly diagnosed type 1 diabetes in the DASP-1 proficiency evaluation. A: The proportion of assays reporting each sample as GAD autoantibody positive on the basis of the laboratory-defined cutoff. B: The rank of individual samples in each assay versus the median rank obtained for all 46 participating assays. Samples are arranged in the order of their median rank in all assays.

Close modal
FIG. 2.

IA-2 autoantibodies in samples from 50 patients with newly diagnosed type 1 diabetes in the DASP-1 proficiency evaluation. A: The proportion of assays reporting each sample as IA-2 autoantibody positive on the basis of the laboratory-defined cutoff. B: The rank of individual samples in each assay versus the median rank obtained for all 44 participating assays. Samples are arranged in the order of their median rank in all assays.

FIG. 2.

IA-2 autoantibodies in samples from 50 patients with newly diagnosed type 1 diabetes in the DASP-1 proficiency evaluation. A: The proportion of assays reporting each sample as IA-2 autoantibody positive on the basis of the laboratory-defined cutoff. B: The rank of individual samples in each assay versus the median rank obtained for all 44 participating assays. Samples are arranged in the order of their median rank in all assays.

Close modal
FIG. 3.

Insulin autoantibodies in samples from 50 patients with newly diagnosed type 1 diabetes in the DASP-1 proficiency evaluation. A: The proportion of assays reporting each sample as insulin autoantibody positive on the basis of the laboratory-defined cutoff. B: The rank of individual samples in each assay versus the median rank obtained for all 23 participating assays. C: The rank of individual samples in each of the 6 assays that achieved the highest sensitivity versus the median rank obtained for all 22 assays. Concordance between these 6 assays was markedly higher than that of the other 16 assays (P < 0.0001). Samples are arranged in the order of their median rank in all assays. The results from each laboratory are indicated by a different symbol.

FIG. 3.

Insulin autoantibodies in samples from 50 patients with newly diagnosed type 1 diabetes in the DASP-1 proficiency evaluation. A: The proportion of assays reporting each sample as insulin autoantibody positive on the basis of the laboratory-defined cutoff. B: The rank of individual samples in each assay versus the median rank obtained for all 23 participating assays. C: The rank of individual samples in each of the 6 assays that achieved the highest sensitivity versus the median rank obtained for all 22 assays. Concordance between these 6 assays was markedly higher than that of the other 16 assays (P < 0.0001). Samples are arranged in the order of their median rank in all assays. The results from each laboratory are indicated by a different symbol.

Close modal
FIG. 4.

GAD autoantibodies (left) and IA-2 autoantibodies (right) in samples from 50 patients with newly diagnosed type 1 diabetes expressed as WHO units/ml. A and B: Box and whisker plots showing interquartile range (▪), median (horizontal line), upper and lower 90th centile (error bars), and outliers (circles and asterisks) for each sample. Index-derived WHO units/ml are shown. Samples are arranged in the order of their median rank in all assays. C and D: The median index-derived versus standard curve-derived WHO units for each sample. The line of identity is represented by a dashed line.

FIG. 4.

GAD autoantibodies (left) and IA-2 autoantibodies (right) in samples from 50 patients with newly diagnosed type 1 diabetes expressed as WHO units/ml. A and B: Box and whisker plots showing interquartile range (▪), median (horizontal line), upper and lower 90th centile (error bars), and outliers (circles and asterisks) for each sample. Index-derived WHO units/ml are shown. Samples are arranged in the order of their median rank in all assays. C and D: The median index-derived versus standard curve-derived WHO units for each sample. The line of identity is represented by a dashed line.

Close modal
FIG. 5.

ROC curve analysis. The area under the ROC curve versus the AS90 calculated from the ROC curve for each GAD antibody assay (○), IA-2 antibody assay (X), and IAA assay (▴).

FIG. 5.

ROC curve analysis. The area under the ROC curve versus the AS90 calculated from the ROC curve for each GAD antibody assay (○), IA-2 antibody assay (X), and IAA assay (▴).

Close modal
TABLE 1

Lab No.Lab-defined sensitivity (%)Lab-defined specificity (%)Area under ROC curve (95% CI)PSensitivity at specificity 90% (AS90 [%])Signal: noise ratioThreshold dilutionAssay typeAntigenLabel
147a 78 98 0.97 (0.93–1.00) <0.0001 92 14 16 RBA Human GAD67(1–101)/ GAD65(96–585) 35
150 88 96 0.97 (0.93–1.00) <0.0001 96 32 64 RBA Human GAD65, Full 125
113 72 98 0.96 (0.93–1.00) <0.0001 92 32 16 RBA Human GAD65, Full 35
114 76 96 0.96 (0.93–1.00) <0.0001 92 37 64 RBA Human GAD65, Full 35
123 78 96 0.96 (0.93–0.99) <0.0001 86 16 RBA Human GAD65, Full 35
116 84 92 0.96 (0.92–0.99) <0.0001 86 23 64 RBA Human GAD65, Full 35
109 74 96 0.95 (0.91–1.00) <0.0001 88 13 16 RBA Human GAD65, Full 35
120 78 96 0.95 (0.90–1.00) <0.0001 93 22 16 RBA Human GAD65, Full 35
121 80 94 0.95 (0.90–1.00) <0.0001 92 23 64 RBA Human GAD65, Full 35
137 78 100 0.94 (0.90–0.99) <0.0001 86 36 16 RBA Human GAD65, Full 35
145 80 90 0.94 (0.90–0.99) <0.0001 84 12 16 RBA Human GAD, 46–586 125
153 82 92 0.94 (0.90–0.99) <0.0001 88 37 64 RBA Human GAD65, Full 35
105 82 90 0.94 (0.89–0.99) <0.0001 86 11 16 RBA Human GAD, 46–586 125
132 84 90 0.94 (0.89–0.99) <0.0001 84 15 16 RBA Human GAD, 46–586 125
155 74 96 0.94 (0.89–0.99) <0.0001 84 RBA Human GAD65, Full 35
140 70 98 0.94 (0.89–0.98) <0.0001 80 RBA Human GAD65, Full 35
152 80 94 0.94 (0.89–0.98) <0.0001 85 RBA Human GAD65, Full 35
126 72 94 0.94 (0.88–0.99) <0.0001 87 11 RBA Human GAD65, Full 35
111 84 98 0.93 (0.88–0.99) <0.0001 86 16 RBA Human GAD65, Full 35
133 84 96 0.93 (0.88–0.99) <0.0001 90 16 RBA Human GAD65, Full 3
115 74 98 0.93 (0.88–0.98) <0.0001 86 RBA Human GAD65, Full 35
124 78 90 0.93 (0.88–0.98) <0.0001 80 64 RBA Human GAD, 46–586 125
156 76 94 0.93 (0.87–0.99) <0.0001 86 42 RBA Human GAD65, Full 35
138 82 96 0.93 (0.87–0.98) <0.0001 86 14 64 RBA Human GAD65, Full 35
144 72 98 0.93 (0.87–0.98) <0.0001 80 16 RBA Human GAD65, Full 35
154 64 100 0.93 (0.87–0.98) <0.0001 85 RBA Human GAD65, Full 35
118 76 94 0.92 (0.87–0.98) <0.0001 80 RBA Human GAD65, Full 35
148 82 92 0.92 (0.87–0.98) <0.0001 84 11 16 RBA Human GAD, 46–586 125
119 70 100 0.92 (0.86–0.98) <0.0001 86 16 16 RBA Human GAD65, Full 35
129 76 98 0.92 (0.86–0.98) <0.0001 78 11 16 RBA Human GAD65, Full 35
139 80 96 0.92 (0.86–0.98) <0.0001 88 17 16 RBA Human GAD65, Full 35
146 82 88 0.92 (0.86–0.98) <0.0001 81 RBA Human GAD65, Full 35
134 78 94 0.91 (0.85–0.97) <0.0001 84 11 RBA Human GAD65, Full 35
136 82 92 0.91 (0.85–0.97) <0.0001 83 16 RBA Human GAD65, Full 35
127 74 98 0.90 (0.84–0.97) <0.0001 83 16 RBA Human GAD65, Full 125
142 80 84 0.90 (0.83–0.96) <0.0001 76 23 16 RBA Human GAD65, Full 35
128 72 98 0.89 (0.83–0.96) <0.0001 78 RBA Human GAD65, Full 35
149 76 84 0.89 (0.83–0.96) <0.0001 74 11 RBA Human GAD65, Full 35
141 76 90 0.89 (0.82–0.95) <0.0001 78 16 RBA Human GAD65, Full 35
110 74 94 0.86 (0.79–0.94) <0.0001 74 RBA Human GAD65, Full 35
147b 76 84 0.86 (0.79–0.94) <0.0001 62 16 RBA Human GAD, 46–586 125
135 58 100 0.86 (0.78–0.94) <0.0001 74 RBA Human GAD65, Full 35
131 66 94 0.85 (0.78–0.93) <0.0001 68 RBA Human GAD65, Full 35
112 60 96 0.85 (0.77–0.93) <0.0001 73 IFMA Human GAD65, Full Europium
117 80 80 0.85 (0.77–0.93) <0.0001 74 16 RBA Human GAD65, Full 35
151 72 92 0.82 (0.73–0.91) <0.0001 76 16 ELISA Human GAD65, Full HRP
Lab No.Lab-defined sensitivity (%)Lab-defined specificity (%)Area under ROC curve (95% CI)PSensitivity at specificity 90% (AS90 [%])Signal: noise ratioThreshold dilutionAssay typeAntigenLabel
147a 78 98 0.97 (0.93–1.00) <0.0001 92 14 16 RBA Human GAD67(1–101)/ GAD65(96–585) 35
150 88 96 0.97 (0.93–1.00) <0.0001 96 32 64 RBA Human GAD65, Full 125
113 72 98 0.96 (0.93–1.00) <0.0001 92 32 16 RBA Human GAD65, Full 35
114 76 96 0.96 (0.93–1.00) <0.0001 92 37 64 RBA Human GAD65, Full 35
123 78 96 0.96 (0.93–0.99) <0.0001 86 16 RBA Human GAD65, Full 35
116 84 92 0.96 (0.92–0.99) <0.0001 86 23 64 RBA Human GAD65, Full 35
109 74 96 0.95 (0.91–1.00) <0.0001 88 13 16 RBA Human GAD65, Full 35
120 78 96 0.95 (0.90–1.00) <0.0001 93 22 16 RBA Human GAD65, Full 35
121 80 94 0.95 (0.90–1.00) <0.0001 92 23 64 RBA Human GAD65, Full 35
137 78 100 0.94 (0.90–0.99) <0.0001 86 36 16 RBA Human GAD65, Full 35
145 80 90 0.94 (0.90–0.99) <0.0001 84 12 16 RBA Human GAD, 46–586 125
153 82 92 0.94 (0.90–0.99) <0.0001 88 37 64 RBA Human GAD65, Full 35
105 82 90 0.94 (0.89–0.99) <0.0001 86 11 16 RBA Human GAD, 46–586 125
132 84 90 0.94 (0.89–0.99) <0.0001 84 15 16 RBA Human GAD, 46–586 125
155 74 96 0.94 (0.89–0.99) <0.0001 84 RBA Human GAD65, Full 35
140 70 98 0.94 (0.89–0.98) <0.0001 80 RBA Human GAD65, Full 35
152 80 94 0.94 (0.89–0.98) <0.0001 85 RBA Human GAD65, Full 35
126 72 94 0.94 (0.88–0.99) <0.0001 87 11 RBA Human GAD65, Full 35
111 84 98 0.93 (0.88–0.99) <0.0001 86 16 RBA Human GAD65, Full 35
133 84 96 0.93 (0.88–0.99) <0.0001 90 16 RBA Human GAD65, Full 3
115 74 98 0.93 (0.88–0.98) <0.0001 86 RBA Human GAD65, Full 35
124 78 90 0.93 (0.88–0.98) <0.0001 80 64 RBA Human GAD, 46–586 125
156 76 94 0.93 (0.87–0.99) <0.0001 86 42 RBA Human GAD65, Full 35
138 82 96 0.93 (0.87–0.98) <0.0001 86 14 64 RBA Human GAD65, Full 35
144 72 98 0.93 (0.87–0.98) <0.0001 80 16 RBA Human GAD65, Full 35
154 64 100 0.93 (0.87–0.98) <0.0001 85 RBA Human GAD65, Full 35
118 76 94 0.92 (0.87–0.98) <0.0001 80 RBA Human GAD65, Full 35
148 82 92 0.92 (0.87–0.98) <0.0001 84 11 16 RBA Human GAD, 46–586 125
119 70 100 0.92 (0.86–0.98) <0.0001 86 16 16 RBA Human GAD65, Full 35
129 76 98 0.92 (0.86–0.98) <0.0001 78 11 16 RBA Human GAD65, Full 35
139 80 96 0.92 (0.86–0.98) <0.0001 88 17 16 RBA Human GAD65, Full 35
146 82 88 0.92 (0.86–0.98) <0.0001 81 RBA Human GAD65, Full 35
134 78 94 0.91 (0.85–0.97) <0.0001 84 11 RBA Human GAD65, Full 35
136 82 92 0.91 (0.85–0.97) <0.0001 83 16 RBA Human GAD65, Full 35
127 74 98 0.90 (0.84–0.97) <0.0001 83 16 RBA Human GAD65, Full 125
142 80 84 0.90 (0.83–0.96) <0.0001 76 23 16 RBA Human GAD65, Full 35
128 72 98 0.89 (0.83–0.96) <0.0001 78 RBA Human GAD65, Full 35
149 76 84 0.89 (0.83–0.96) <0.0001 74 11 RBA Human GAD65, Full 35
141 76 90 0.89 (0.82–0.95) <0.0001 78 16 RBA Human GAD65, Full 35
110 74 94 0.86 (0.79–0.94) <0.0001 74 RBA Human GAD65, Full 35
147b 76 84 0.86 (0.79–0.94) <0.0001 62 16 RBA Human GAD, 46–586 125
135 58 100 0.86 (0.78–0.94) <0.0001 74 RBA Human GAD65, Full 35
131 66 94 0.85 (0.78–0.93) <0.0001 68 RBA Human GAD65, Full 35
112 60 96 0.85 (0.77–0.93) <0.0001 73 IFMA Human GAD65, Full Europium
117 80 80 0.85 (0.77–0.93) <0.0001 74 16 RBA Human GAD65, Full 35
151 72 92 0.82 (0.73–0.91) <0.0001 76 16 ELISA Human GAD65, Full HRP
TABLE 2

IA-2 autoantibody assays

Lab No.Lab-defined sensitivity (%)Lab-defined specificity (%)Area under ROC curve (95% CI)PSensitivity at specificity 90% (AS90 [%])Signal: noise ratioThreshold dilutionAssay typeAntigenLabel
115 62 98 0.90 (0.84–0.96) <0.0001 74 37 64 RBA hu IA-2 ic 35
150 58 100 0.86 (0.79–0.94) <0.0001 72 13 64 RBA hu IA-2 ic 125
128 56 98 0.84 (0.76–0.94) <0.0001 62 15 16 RBA hu IA-2 ic 35
133a 52 100 0.84 (0.75–0.92) <0.0001 64 90 64 RBA hu IA-2 bdc 35
144 54 100 0.83 (0.75–0.91) <0.0001 58 64 64 RBA hu IA-2 ic 35
132 58 100 0.83 (0.74–0.91) <0.0001 66 22 64 RBA hu IA-2 ic 125
113 60 92 0.83 (0.74–0.91) <0.0001 68 141 16 RBA hu IA-2 ic 35
136 58 100 0.82 (0.74–0.91) <0.0001 68 RBA hu IA-2 ic 35
156 57 100 0.82 (0.73–0.91) <0.0001 67  64 RBA hu IA-2 ic 35
135 58 94 0.82 (0.73–0.90) <0.0001 62 24 16 RBA hu IA-2 bdc/ic 35
109 52 98 0.81 (0.72–0.90) <0.0001 66 17 64 RBA Full length IA-2 35
145 58 100 0.81 (0.71–0.90) <0.0001 72 20 RBA hu IA-2 ic 125
124 58 100 0.81 (0.71–0.90) <0.0001 68 12 16 RBA hu IA-2 ic 125
147 72 60 0.80 (0.71–0.88) <0.0001 56 RBA hu ICA512, 1–979 35
105 58 98 0.80 (0.70–0.89) <0.0001 68 11 RBA hu IA-2 ic 125
138 60 98 0.79 (0.69–0.89) <0.0001 68 74 64 RBA hu IA-2 ic 35
152 60 94 0.79 (0.69–0.88) <0.0001 62 21 RBA hu IA-2 ic 35
126 56 100 0.79 (0.69–0.88) <0.0001 61 56 64 RBA hu IA-2 ic 35
111 56 100 0.78 (0.69–0.88) <0.0001 62 106 64 RBA hu IA-2 ic 35
155 50 100 0.78 (0.68–0.87) <0.0001 58 11 64 RBA Full length IA-2 35
137 54 100 0.77 (0.68–0.87) <0.0001 58 138 RBA hu IA-2 ic 35
140 56 100 0.77 (0.67–0.87) <0.0001 56 101 64 RBA hu IA-2 ic 35
129 54 100 0.77 (0.67–0.87) <0.0001 58 46 64 RBA hu IA-2 ic 35
133b 57 100 0.76 (0.66–0.86) <0.0001 59  No standard curve RBA hu IA-2 ic 35
123 54 100 0.76 (0.66–0.86) <0.0001 62 111 64 RBA hu IA-2 ic 35
131 88 28 0.75 (0.66–0.85) <0.0001 52 21 RBA hu IA-2 ic 35
149 54 92 0.75 (0.65–0.85) <0.0001 50 72 64 RBA hu IA-2 bdc 35
148 58 100 0.75 (0.65–0.85) <0.0001 58 105 64 RBA hu IA-2 ic 35
134 56 98 0.75 (0.65–0.85) <0.0001 58 25 16 RBA hu IA-2 ic 35
118 54 96 0.75 (0.65–0.85) <0.0001 54 47 16 RBA hu IA-2 bdc 35
121 58 100 0.74 (0.64–0.85) <0.0001 58 120 64 RBA hu IA-2 ic 35
146 52 98 0.73 (0.63–0.84) <0.0001 60 17 64 RBA hu IA-2 bdc 35
107 50 94 0.73 (0.63–0.83) <0.0001 52 35 ELISA hu IA-2 ic HRP
153 58 100 0.73 (0.62–0.83) <0.0001 59 62 64 RBA hu IA-2 ic 35
117 58 74 0.72 (0.62–0.82) <0.0001 54 44 64 RBA hu IA-2 bdc 35
151 54 90 0.71 (0.60–0.83) <0.0001 54 27 ELISA hu IA-2 ic HRP
139 58 100 0.71 (0.60–0.82) <0.0001 59 85 64 RBA hu IA-2 ic 35
116 58 98 0.71 (0.59–0.82) <0.0001 58 114 64 RBA hu IA-2 ic 35
120 58 90 0.70 (0.59–0.81) <0.0001 58 128 64 RBA hu IA-2 ic 35
141 48 98 0.70 (0.59–0.80) 0.001 50 39 64 RBA hu IA-2 bdc 35
142 50 96 0.70 (0.58–0.81) 0.001 56 118 64 RBA hu IA-2 bdc 3H
114 58 100 0.68 (0.56–0.79) 0.003 58 132 64 RBA hu IA-2 ic 35
119 50 100 0.65 (0.54–0.77) <0.0001 52 27 16 RBA hu IA-2 bdc 35
110 52 94 0.65 (0.53–0.77) 0.011 54 31 64 RBA hu IA-2 bdc 35
Lab No.Lab-defined sensitivity (%)Lab-defined specificity (%)Area under ROC curve (95% CI)PSensitivity at specificity 90% (AS90 [%])Signal: noise ratioThreshold dilutionAssay typeAntigenLabel
115 62 98 0.90 (0.84–0.96) <0.0001 74 37 64 RBA hu IA-2 ic 35
150 58 100 0.86 (0.79–0.94) <0.0001 72 13 64 RBA hu IA-2 ic 125
128 56 98 0.84 (0.76–0.94) <0.0001 62 15 16 RBA hu IA-2 ic 35
133a 52 100 0.84 (0.75–0.92) <0.0001 64 90 64 RBA hu IA-2 bdc 35
144 54 100 0.83 (0.75–0.91) <0.0001 58 64 64 RBA hu IA-2 ic 35
132 58 100 0.83 (0.74–0.91) <0.0001 66 22 64 RBA hu IA-2 ic 125
113 60 92 0.83 (0.74–0.91) <0.0001 68 141 16 RBA hu IA-2 ic 35
136 58 100 0.82 (0.74–0.91) <0.0001 68 RBA hu IA-2 ic 35
156 57 100 0.82 (0.73–0.91) <0.0001 67  64 RBA hu IA-2 ic 35
135 58 94 0.82 (0.73–0.90) <0.0001 62 24 16 RBA hu IA-2 bdc/ic 35
109 52 98 0.81 (0.72–0.90) <0.0001 66 17 64 RBA Full length IA-2 35
145 58 100 0.81 (0.71–0.90) <0.0001 72 20 RBA hu IA-2 ic 125
124 58 100 0.81 (0.71–0.90) <0.0001 68 12 16 RBA hu IA-2 ic 125
147 72 60 0.80 (0.71–0.88) <0.0001 56 RBA hu ICA512, 1–979 35
105 58 98 0.80 (0.70–0.89) <0.0001 68 11 RBA hu IA-2 ic 125
138 60 98 0.79 (0.69–0.89) <0.0001 68 74 64 RBA hu IA-2 ic 35
152 60 94 0.79 (0.69–0.88) <0.0001 62 21 RBA hu IA-2 ic 35
126 56 100 0.79 (0.69–0.88) <0.0001 61 56 64 RBA hu IA-2 ic 35
111 56 100 0.78 (0.69–0.88) <0.0001 62 106 64 RBA hu IA-2 ic 35
155 50 100 0.78 (0.68–0.87) <0.0001 58 11 64 RBA Full length IA-2 35
137 54 100 0.77 (0.68–0.87) <0.0001 58 138 RBA hu IA-2 ic 35
140 56 100 0.77 (0.67–0.87) <0.0001 56 101 64 RBA hu IA-2 ic 35
129 54 100 0.77 (0.67–0.87) <0.0001 58 46 64 RBA hu IA-2 ic 35
133b 57 100 0.76 (0.66–0.86) <0.0001 59  No standard curve RBA hu IA-2 ic 35
123 54 100 0.76 (0.66–0.86) <0.0001 62 111 64 RBA hu IA-2 ic 35
131 88 28 0.75 (0.66–0.85) <0.0001 52 21 RBA hu IA-2 ic 35
149 54 92 0.75 (0.65–0.85) <0.0001 50 72 64 RBA hu IA-2 bdc 35
148 58 100 0.75 (0.65–0.85) <0.0001 58 105 64 RBA hu IA-2 ic 35
134 56 98 0.75 (0.65–0.85) <0.0001 58 25 16 RBA hu IA-2 ic 35
118 54 96 0.75 (0.65–0.85) <0.0001 54 47 16 RBA hu IA-2 bdc 35
121 58 100 0.74 (0.64–0.85) <0.0001 58 120 64 RBA hu IA-2 ic 35
146 52 98 0.73 (0.63–0.84) <0.0001 60 17 64 RBA hu IA-2 bdc 35
107 50 94 0.73 (0.63–0.83) <0.0001 52 35 ELISA hu IA-2 ic HRP
153 58 100 0.73 (0.62–0.83) <0.0001 59 62 64 RBA hu IA-2 ic 35
117 58 74 0.72 (0.62–0.82) <0.0001 54 44 64 RBA hu IA-2 bdc 35
151 54 90 0.71 (0.60–0.83) <0.0001 54 27 ELISA hu IA-2 ic HRP
139 58 100 0.71 (0.60–0.82) <0.0001 59 85 64 RBA hu IA-2 ic 35
116 58 98 0.71 (0.59–0.82) <0.0001 58 114 64 RBA hu IA-2 ic 35
120 58 90 0.70 (0.59–0.81) <0.0001 58 128 64 RBA hu IA-2 ic 35
141 48 98 0.70 (0.59–0.80) 0.001 50 39 64 RBA hu IA-2 bdc 35
142 50 96 0.70 (0.58–0.81) 0.001 56 118 64 RBA hu IA-2 bdc 3H
114 58 100 0.68 (0.56–0.79) 0.003 58 132 64 RBA hu IA-2 ic 35
119 50 100 0.65 (0.54–0.77) <0.0001 52 27 16 RBA hu IA-2 bdc 35
110 52 94 0.65 (0.53–0.77) 0.011 54 31 64 RBA hu IA-2 bdc 35
TABLE 3

Insulin autoantibody assays

Lab no.Lab-defined sensitivity (%)Lab-defined specificity (%)Area under ROC curve (95% CI)PSensitivity at specificity 90% (AS90 [%])Assay typeAntigenLabel
116 36 100 0.80 (0.71–0.90) <0.0001 66 RBA Human insulin 125
120 32 100 0.77 (0.68–0.86) <0.0001 52 RBA Human insulin 125
133 14 100 0.77 (0.68–0.86) <0.0001 47 RBA Human insulin 125
153 34 98 0.77 (0.68–0.87) <0.0001 64 RBA Human insulin 125
121 30 98 0.75 (0.66–0.85) <0.0001 47 RBA Human insulin 125
126 16 100 0.75 (0.65–0.88) <0.0001 51 RBA Human insulin 125
156 100 0.73 (0.62–0.83) <0.0001 56 RBA Human insulin 125
148 42 98 0.72 (0.62–0.82) <0.0001 50 RBA Human insulin 125
118 10 98 0.70 (0.60–0.81) <0.0001 36 RBA Human insulin 125
138 100 0.63 (0.58–0.79) 0.002 32 RBA Human insulin 125
140 14 100 0.68 (0.57–0.78) 0.003 40 RBA Human insulin 125
115 16 100 0.67 (0.57–0.78) 0.003 42 RBA Human insulin 125
113 12 100 0.66 (0.55–0.77) 0.006 30 RBA Human insulin 125
123 30 90 0.65 (0.54–0.76) 0.012 26 RBA Human insulin 125
137 96 0.64 (0.53–0.75) 0.014 29 RBA Human insulin 125
149 98 0.62 (0.51–0.73) 0.033 21 RBA Human insulin 125
145 100 0.62 (0.50–0.73) 0.044 38 RBA Human insulin 125
114 14 100 0.59 (0.48–0.70) 0.121 26 RBA Human insulin 125
117 16 98 0.58 (0.47–0.70) 0.155 25 RBA Human insulin 125
132 100 0.58 (0.44–0.67) 0.324 19 RBA Human insulin 125
135 100 0.55 (0.43–0.66) 0.404 19 RBA Human insulin 125
136 20 94 0.52 (0.40–0.63) 0.746 21 RBA Human insulin 125
105 100 0.32 (0.21–0.42) 0.002 13 RBA Human insulin 125
Lab no.Lab-defined sensitivity (%)Lab-defined specificity (%)Area under ROC curve (95% CI)PSensitivity at specificity 90% (AS90 [%])Assay typeAntigenLabel
116 36 100 0.80 (0.71–0.90) <0.0001 66 RBA Human insulin 125
120 32 100 0.77 (0.68–0.86) <0.0001 52 RBA Human insulin 125
133 14 100 0.77 (0.68–0.86) <0.0001 47 RBA Human insulin 125
153 34 98 0.77 (0.68–0.87) <0.0001 64 RBA Human insulin 125
121 30 98 0.75 (0.66–0.85) <0.0001 47 RBA Human insulin 125
126 16 100 0.75 (0.65–0.88) <0.0001 51 RBA Human insulin 125
156 100 0.73 (0.62–0.83) <0.0001 56 RBA Human insulin 125
148 42 98 0.72 (0.62–0.82) <0.0001 50 RBA Human insulin 125
118 10 98 0.70 (0.60–0.81) <0.0001 36 RBA Human insulin 125
138 100 0.63 (0.58–0.79) 0.002 32 RBA Human insulin 125
140 14 100 0.68 (0.57–0.78) 0.003 40 RBA Human insulin 125
115 16 100 0.67 (0.57–0.78) 0.003 42 RBA Human insulin 125
113 12 100 0.66 (0.55–0.77) 0.006 30 RBA Human insulin 125
123 30 90 0.65 (0.54–0.76) 0.012 26 RBA Human insulin 125
137 96 0.64 (0.53–0.75) 0.014 29 RBA Human insulin 125
149 98 0.62 (0.51–0.73) 0.033 21 RBA Human insulin 125
145 100 0.62 (0.50–0.73) 0.044 38 RBA Human insulin 125
114 14 100 0.59 (0.48–0.70) 0.121 26 RBA Human insulin 125
117 16 98 0.58 (0.47–0.70) 0.155 25 RBA Human insulin 125
132 100 0.58 (0.44–0.67) 0.324 19 RBA Human insulin 125
135 100 0.55 (0.43–0.66) 0.404 19 RBA Human insulin 125
136 20 94 0.52 (0.40–0.63) 0.746 21 RBA Human insulin 125
105 100 0.32 (0.21–0.42) 0.002 13 RBA Human insulin 125
1
Bingley PJ, Bonifacio E, Ziegler AG, Schatz DA, Atkinson MA, Eisenbarth GS on behalf of the Immunology of Diabetes Society: Proposed guidelines in screening for risk of type 1 diabetes.
Diabetes Care
24
:
398
–398,
2001
2
Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R, UK Prospective Diabetes Study Group: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes.
Lancet
350
:
1288
–1293,
1997
3
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care
20
:
1183
–1197,
1997
4
Ziegler AG, Hummel M, Schenker M, Bonifacio E: Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study.
Diabetes
48
:
460
–468,
1999
5
Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffie RS, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA: Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY).
Diabetologia
39
:
807
–812,
1996
6
Bonifacio E, Boitard C, Gleichman H, Shattock MA, Molenaar JL, Bottazzo GF: Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurements in 41 assays.
Diabetologia
33
:
731
–736,
1990
7
Bottazzo GF, Gleichmann H: Immunology and Diabetes Workshops: report of the First International Workshop on Standardisation of Cytoplasmic Islet Cell Antibodies.
Diabetologia
29
:
125
–126,
1986
8
Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS: Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop.
Diabetes
47
:
1857
–1866,
1998
9
Mire-Sluis AR, Gaines Das R, Lernmark Å: The World Health Organization International Collaborative Study for islet cell antibodies.
Diabetologia
43
:
1282
–1292,
2000
10
Williams AJK, Bingley PJ, Bonifacio E, Palmer JP, Gale EAM: A novel micro-assay for insulin autoantibodies.
J Autoimmun
10
:
473
–478,
1997
11
Naserke HE, Dozio N, Ziegler AG, Bonifacio E: Comparison of a novel micro-assay for insulin autoantibodies with the conventional radiobinding assay.
Diabetologia
41
:
681
–683,
1998
12
Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS: Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes.
Proc Natl Acad Sci U S A
97
:
1701
–1706,
2000
13
Vardi P, Dib SA, Tuttleman M, Connelly JE, Grinbergs M, Radizabeh A, Riley WJ, Maclaren NK, Eisenbarth GS, Soeldner JS: Competitive insulin autoantibody assay: prospective evaluation of subjects at high risk for development of type 1 diabetes mellitus.
Diabetes
36
:
1286
–1291,
1987

Address correspondence and reprint requests to Dr. Polly J. Bingley, Diabetes and Metabolism, Medical School Unit, Southmead Hospital, Bristol BS10 5NB, U.K. E-mail: polly.bingley@bristol.ac.uk.

Received for publication 12 October 2002 and accepted in revised form 21 January 2003.

AS90, adjusted sensitivity90; AUC, area under the curve; DASP, Diabetes Antibody Standardization Program; ELISA, enzyme-linked immunosorbent assay; IAA, insulin autoantibody; ICA, islet cell antibody; ROC, receiver operator characteristic; WHO, World Health Organization.